This case focuses on the development of AZT, the first drug approved for the treatment of AIDS, as well as issues facing the British producer, Wellcome PLC, as it decides how to set the price of the drug. The case includes a brief overview of the disease, in the development of drugs to treat it, the pharmaceutical industry and its practices and history of the Wellcome PLC and its U.S. subsidiary, Burroughs Wellcome. The case concludes with analysts' forecasts for the soon-to-be-announced price of AZT. See also the B case and the case of C. "Hide
by Jeanne M. Liedtka Source: Darden School of Business 9 pages. Publication date: April 15, 1991. Prod. #: UV0237-PDF-ENG
Related Case Solutions & Analyses:
Mobileye: The Future of Driverless Cars
Beleza Natural
Cutting Out the Middle-Man: The Case for Direct Business Involvement in Environmental Justice
Low-Carbon, Indigenous Innovation in China
iPierian
Pepsi-BASIX Partnership
Developing a Teaching Case (C): Virtualis Systems Case Feedback
Royal Dutch/Shell in Transition (B)
Nordstrom: Dissension in the Ranks? (A), Spanish Version
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
